KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Equity Average (2016 - 2025)

West Pharmaceutical Services' Equity Average history spans 16 years, with the latest figure at $3.0 billion for Q3 2025.

  • For Q3 2025, Equity Average rose 12.23% year-over-year to $3.0 billion; the TTM value through Sep 2025 reached $3.0 billion, up 12.23%, while the annual FY2024 figure was $2.8 billion, 0.05% changed from the prior year.
  • Equity Average for Q3 2025 was $3.0 billion at West Pharmaceutical Services, up from $2.8 billion in the prior quarter.
  • Across five years, Equity Average topped out at $3.0 billion in Q3 2025 and bottomed at $1.8 billion in Q1 2021.
  • The 5-year median for Equity Average is $2.7 billion (2024), against an average of $2.5 billion.
  • The largest annual shift saw Equity Average grew 27.36% in 2021 before it fell 5.48% in 2024.
  • A 5-year view of Equity Average shows it stood at $2.3 billion in 2021, then grew by 13.62% to $2.6 billion in 2022, then rose by 11.51% to $2.9 billion in 2023, then decreased by 5.48% to $2.7 billion in 2024, then rose by 10.05% to $3.0 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Equity Average are $3.0 billion (Q3 2025), $2.8 billion (Q2 2025), and $2.7 billion (Q1 2025).